L'intérêt à découvert pour AEye donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de AEye. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

AEye (NASDAQ:LIDR) Stock, Rapport sur les intérêts à découvert

AEye

AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.

AEye Inc

<figure class="wp-block-image size-large"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2025/07/2025-07-28_08h19_11.png" alt="" /></figure>
To gain an edge, this is what you need to know today.
<h4 class="wp-block-heading">Big Tech Earnings</h4>
Please <a href="https://thearorareport.com/stock-market-chart-analysis-big-tech-earnings-msft-mc-07282025">click here</a> for an enlarged chart of Microsoft Corp (MSFT).
Note the following:
<ul class="wp-block-list">
<li>This article is about the big picture, not an individual stock.  The chart of Microsoft Corp (MSFT) stock is being used to illustrate the point.</li>
<li>The chart shows our buy signal on MSFT on the April drop.  The chart also shows MSFT stock dipping into our buy zone.</li>
<li>The chart shows the gap up in MSFT stock on its previous earnings report.</li>
<li>The chart shows the run up in MSFT stock since then.</li>
<li>The chart shows MSFT stock hitting new highs after it broke out of zone 1 (previously resistance, now support).</li>
<li>RSI on the chart shows MSFT stock is not overbought despite its rapid rise.</li>
<li>The near term direction of the stock market will depend on big tech earnings reported this week. 
<ul class="wp-block-list">
<li>Microsoft and Meta Platforms Inc (META) report earnings on Wednesday after the regular session close.  Apple Inc (AAPL) and Amazon.com, Inc. (AMZN) report earnings on Thursday after the regular session close.</li>
<li>The bar is high for Microsoft, Meta, Apple, and Amazon earnings.&nbsp; Whisper numbers are higher than consensus numbers.&nbsp; Whisper numbers are the numbers analysts privately share with their best clients.&nbsp; Whisper numbers are often different from consensus numbers published by the same analysts for public consumption.&nbsp; Analysts typically provide whisper numbers only to their best clients, and not the public.</li>
</ul>
</li>
<li>Of note, Amazon CEO Jeff Bezos sold more AMZN stock, nearly $1B worth.</li>
<li>There is buying in the early trade on optimism about the trade deal with Europe.&nbsp; Please see the section below.</li>
</ul>
<h4 class="wp-block-heading">European Union</h4>
Trade between the U.S. and the E.U. accounts for nearly a third of global trade.&nbsp; The E.U. and the U.S. have agreed on a framework for a trade deal which will impose a 15% tariff on most goods from the U.S.&nbsp; The E.U. will also purchase $750B in energy from the U.S. in addition to a separate $600B investment.
<h4 class="wp-block-heading">China</h4>
U.S. and Chinese officials are meeting in Sweden to extend the deadline for reaching a trade deal.
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in AAPL, AMZN, NVIDIA Corp (NVDA), MSFT, Alphabet Inc Class C (GOOG), META, and Tesla (TSLA).
In the early trade, money flows are positive in SPDR S&amp;P 500 ETF Trust (SPY) and Invesco QQQ Trust Series 1 (QQQ).
<h4 class="wp-block-heading">Oil</h4>
There is speculation that Saudi Arabia is looking at a price hike in September for Asia.
<h4 class="wp-block-heading">Bitcoin</h4>
Bitcoin (BTC) is range bound.
What to do now
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.  The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.  If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.  When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.  High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content or accuracy.
&#x2A;&#x2A;
Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Equities

Market Summary

Opinion

Markets

Trading Ideas

Market Direction Depends On Amazon, Meta, Microsoft, And Apple Clearing The High Bar

Piper Sandler analyst Paul Newsome maintains Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) with a Overweight and raises the price target from $393 to $413.

News

Price Target

Analyst Ratings

Piper Sandler Maintains Overweight on Aon, Raises Price Target to $413

JP Morgan analyst Bill Peterson maintains Kaiser Aluminum (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALU#NASDAQ">KALU</a>) with a Neutral and raises the price target from $64 to $82.

KALU

JP Morgan Maintains Neutral on Kaiser Aluminum, Raises Price Target to $82

Piper Sandler analyst Stephen Scouten maintains Amerant Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMTB#NYSE">AMTB</a>) with a Overweight and raises the price target from $25 to $26.

AMTB

Piper Sandler Maintains Overweight on Amerant Bancorp, Raises Price Target to $26

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) has outperformed the market over the past 10 years by 11.95% on an annualized basis producing an average annual return of 23.72%. Currently, Ascendis Pharma has a market capitalization of $10.31 billion. 
Buying $100 In ASND: If an investor had bought $100 of ASND stock 10 years ago, it would be worth $847.85 today based on a price of $170.50 for ASND at the time of writing.
<h3>Ascendis Pharma's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753717514_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASND

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Piper Sandler analyst Ryan Todd maintains Darling Ingredients (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAR#NYSE">DAR</a>) with a Overweight and lowers the price target from $54 to $50.

Piper Sandler Maintains Overweight on Darling Ingredients, Lowers Price Target to $50

Piper Sandler analyst Ryan Todd maintains Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) with a Neutral and lowers the price target from $147 to $144.

Piper Sandler Maintains Neutral on Phillips 66, Lowers Price Target to $144

Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) is likely to report upbeat revenue and earnings for the fiscal third quarter, with "upsides across the board," according to JPMorgan.
The Qualcomm Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ac4af2b85e930001e6383f/samik-chatterjee">Analyst Samik Chatterjee</a> reiterated an Overweight rating, while raising the price target from $190 to $200.
The Qualcomm Thesis: While the company is gearing up to report results against a low bar, its guidance for the fiscal fourth quarter "is likely to surprise investors positively," Chatterjee said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Investor expectations are low due to the weak monthly sales data reported by MediaTek Inc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MDTTF#OTC">MDTTF</a>), muted smartphone sales growth in the second quarter, and the impact of the share loss at Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), the analyst stated.
Despite the loss of Apple revenues, the resilience of Qualcomm's revenue outlook would highlight the success of its diversification strategy, with "new efforts around expansion into the Datacenter TAM likely to provide further legs to the non-Smartphone growth drivers in time," he wrote.
In the smartphone market, the high-end range is likely to have performed better, which would help Qualcomm generate low double-digit revenue growth in the fiscal third and fourth quarters, he added.
Price Action: Shares of Qualcomm had risen by 1.50% to $160.77 at the time of publication on Monday.
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/entertainment/25/07/46371957/netflixs-squid-game-reality-show-gets-season-2-date-4-56-million-prize-without-the-killing">How Taiwan Is Betting Big On AI To Power Its Economy</a></li>
</ul>
Image: Shutterstock

Analyst Color

Previews

Reiteration

AAPL

MDTTF

QCOM

Qualcomm May Have Lost Apple, But It's Not Losing Steam: Analyst

Piper Sandler analyst Ryan Todd maintains Valero Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) with a Overweight and raises the price target from $159 to $168.

Piper Sandler Maintains Overweight on Valero Energy, Raises Price Target to $168

JP Morgan analyst Ryan Brinkman maintains Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) with a Neutral and raises the price target from $37 to $38.

THRM

JP Morgan Maintains Neutral on Gentherm, Raises Price Target to $38

Piper Sandler analyst Peter Keith maintains Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) with a Overweight and raises the price target from $184 to $185.

BOOT

Piper Sandler Maintains Overweight on Boot Barn Holdings, Raises Price Target to $185

JP Morgan analyst Stephen Tusa maintains Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>) with a Overweight and raises the price target from $211 to $217.

JP Morgan Maintains Overweight on Dover, Raises Price Target to $217

Rumors

Watching DLocal; Shares See Volume To The Upside, Traders Circulate Stock Picked By Zacks Blockchain Innovators

Legendary investor Warren Buffett has a long track record of <a href="https://www.benzinga.com/general/education/25/01/42832123/warren-buffett-beats-sp-500-in-2024-how-oracle-of-omahas-returns-compare-over-past-20-years">outperforming the S&amp;P 500</a> and broad stock market indexes. Buffett's Berkshire Hathaway Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) has fallen behind the S&amp;P 500 in 2025 and risks underperforming for the full year.
What Happened: The Berkshire Hathaway conglomerate owns numerous companies and also <a href="https://www.benzinga.com/general/education/25/05/45208955/warren-buffetts-giant-berkshire-portfolio-top-10-includes-banks-oil-and-apple" target="_blank" rel="noopener">holds a substantial investment portfolio, </a>which Buffett and the late Charlie Munger have managed for years.
With Buffett set to step down as CEO, the investment portfolio will shift more and more to his successor Greg Abel.
For years, Berkshire Hathaway outperformed the market, but in recent years the gap has closed and the legendary investor has been closer to the average returns of the S&amp;P 500, which is tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>).
Year-to-date in 2025, Berkshire Hathaway is up 7.3%, trailing the 9.0% gain for the SPDR S&amp;P 500 ETF Trust.
There are numerous reasons for the underperformance, but a review of Berkshire Hathaway&#8217;s top stock holdings and their performance may reveal one of the primary reasons. Here are the current top holdings of Berkshire Hathaway's investment portfolio and their current year-to-date performance.
<ul class="wp-block-list">
<li>Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>): -12.3%</li>
<li>American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>): +4.4%</li>
<li>Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>): +9.4%</li>
<li>Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): +11.9%</li>
<li>Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>): +5.5%</li>
<li>Moody's Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>): +8.5%</li>
<li>Occidental Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>): -10.2%</li>
<li>Kraft Heinz Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>): -6.8%</li>
<li>Mitsubishi: +15.6%</li>
<li>Chubb Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>): -1.2%</li>
</ul>
Of the top 10 stock holdings, four have negative returns on the year. Only three of the top holdings are outperforming the S&amp;P 500 and the biggest gainer for the year among the top 10 stock holdings is Mitsubishi up 15.6%.
Apple, which is the largest holding of the stock portfolio, representing around 21%, is down over 12% year-to-date. The large tech giant has helped boost the performance of Berkshire Hathaway in recent years, but in 2025, it could help the conglomerate underperform the overall market.
Read Also: <a href="https://www.benzinga.com/news/education/25/07/46264430/why-warren-buffett-says-stocks-arent-what-hes-really-buying">Why Warren Buffett Says Stocks Aren&#8217;t What He&#8217;s Really Buying</a>
Why It's Important: Berkshire Hathaway was up 27.1% in 2024, outperforming the 24.1% gain of the S&amp;P 500 last year. Over the past 20 years, Berkshire Hathaway has beaten the S&amp;P 500 11 times.
However, over the last 10 years, the returns have been even, with five wins for Berkshire Hathaway and five for the S&amp;P 500.
Berkshire Hathaway has averaged gains of 12.1% over the last 20 years, compared to 11.5% for the S&amp;P 500.
The year 2025 could bring these numbers more into line with the S&amp;P 500 and end Buffett's legacy of running Berkshire Hathaway on a negative note.
The good news is it's only one year, and investors will likely remember the strong returns Buffett and Berkshire had for decades before the recent underperformance.
Abel and the new Berkshire Hathaway team may need to put some of the $347 cash pile the company is holding to work to generate strong returns going forward. Recent reports suggest that Berkshire Hathaway is poised to make another move in <a href="https://www.benzinga.com/trading-ideas/rumors/25/07/46557532/is-warren-buffetts-347-billion-cash-buying-railroads-heres-what-the-oracle-of-omaha-said">the railroad sector.</a>
An October 2024 <a href="https://www.benzinga.com/news/management/24/10/41302268/buffett-vs-musk-benzinga-readers-see-an-overwhelming-favorite-to-go-down-as-the-best-investor-in-">Benzinga poll</a> asked readers about Buffett's legacy.
&#8220;In 100 years, who&#8217;s going to be remembered as the most legendary investor?&#8221; Benzinga asked.
Here were the results:
<ul class="wp-block-list">
<li>Warren Buffett: 61%</li>
<li>Elon Musk: 30%</li>
<li>Jeff Bezos: 6%</li>
<li>Mark Cuban: 4%</li>
</ul>
The poll found that Buffett is most likely to be remembered as a legendary investor in the next 100 years by a two-to-one margin.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/education/25/05/45602754/warren-buffett-investment-success-3-simple-rules-to-copy-oracle-of-omaha">Warren Buffett Investment Success: 3 Simple Rules To Copy Oracle Of Omaha</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Long Ideas

Management

Is Apple Sinking Warren Buffett's Portfolio? The Oracle Of Omaha's Winning Streak Faces Collapse

JP Morgan analyst Jeremy Tonet maintains Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) with a Overweight and raises the price target from $380 to $390.

JP Morgan Maintains Overweight on Constellation Energy, Raises Price Target to $390

JP Morgan analyst Seth Seifman maintains Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) with a Underweight and raises the price target from $115 to $122.

JP Morgan Maintains Underweight on Booz Allen Hamilton, Raises Price Target to $122

Macro Economic Events

Politics

Global

Economics

General

Reuters Cites Brazil's Lula Saying Hope Trump Will Think About Brazil's Importance, Negotiate Tariffs

Chinese biotech company Hengrui Pharma partnered with GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) on Monday to <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">develop up to 12 medicines</a>.
These agreements will add significant value to Hengrui&#8217;s globalization strategy and provide GSK with significant new growth opportunities beyond 2031.
The programs were selected to complement GSK&#8217;s extensive Respiratory, Immunology &amp; Inflammation (RI&amp;I) and Oncology pipeline.
Also Read: <a href="https://www.benzinga.com/news/fda/25/07/46607015/gsks-blood-cancer-drug-review-extended-as-fda-seeks-more-data" target="_blank" rel="noreferrer noopener">GSK&#8217;s Blood Cancer Drug Review Extended As FDA Seeks More Data</a>
GSK will pay $500 million in upfront fees across the agreements.
The agreements include an exclusive worldwide license (excluding mainland China, Hong Kong SAR, Macau SAR, and Taiwan region) for (HRS-9821) in clinical development for chronic obstructive pulmonary disease (COPD) as an add-on maintenance treatment, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46651745/hengrui-pharma-and-gsk-enter-agreements-to-develop-up-to-12-innovative-medicines-across-respirator" rel="noreferrer noopener">irrespective of background therapy</a>.
HRS-9821 has demonstrated potent PDE3 and PDE4 inhibition, leading to increased bronchodilation and anti-inflammatory effects in early clinical and preclinical studies.
In addition, HRS-9821 provides the opportunity for a convenient dry-powder inhaler (DPI) formulation that strategically fits GSK&#8217;s established inhaled portfolio.
The agreements also include a scaled collaboration to generate up to 11 programs in addition to HRS-9821, each with its financial structure.
Hengrui Pharma will lead the development of these programs up to completion of phase I trials. Patients outside of China will participate.
GSK may commercialize each program, except for those in China, Hong Kong, Macau, and Taiwan, at the end of phase 1.
Tony Wood, Chief Scientific Officer, GSK, said: &#8220;This deal reflects our strategic investment in programs that address validated targets, increasing the likelihood of success, and with the option to advance those assets with the greatest potential for patient impact.&#8221;
The collaboration enables scale and speed to proof-of-concept to develop up to 11 additional innovative medicines.&#8221;
If all programs are optioned and all milestones are achieved, the potential total value of future success-based development, regulatory, and commercial milestone payments to Hengrui Pharma is approximately $12 billion.
In addition, Hengrui Pharma will be eligible to receive tiered royalties on global product net sales (excluding mainland China, Hong Kong SAR, Macau SAR, and Taiwan region).
In March, Merck &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Hengrui Pharma entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44477157/merck-partners-with-hengrui-pharma-in-177-billion-deal-for-cardiovascular-treatment" rel="noreferrer noopener">Phase 2 trial in China</a>.
Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, excluding the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44470230/merck-enters-exclusive-license-agreement-for-hrs-5346-an-investigational-oral-lipoprotein-a-inhibi" rel="noreferrer noopener">Greater China region</a>.
Hengrui Pharma will receive an upfront payment of $200 million and is eligible to receive milestone payments associated with certain development, regulatory, and commercial milestones up to $1.77 billion and royalties on net sales of HRS-5346 if approved.
Price Action: GSK stock is down 0.74% at $37.69 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46657204/sharplink-gaming-stock-climbs-over-5-in-monday-pre-market-whats-going-on" target="_blank" rel="noreferrer noopener">SharpLink Gaming Stock Climbs Over 5% In Monday Pre-Market: What&#8217;s Going On?</a></li>
</ul>
Image: Shutterstock

Biotech

Large Cap

Health Care

Contracts

After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact

PFSA

Profusa Shares Halted On Circuit Breaker To The Upside, Stock Now Up 66.1%

Guidance

Fomento Economico Mexicano S.A.B. De C.V.

Reuters Cites Mexico's FEMSA CFO Saying Sustained Weakness In Traffic In Mexico Is The Focal Point For The Co's Commercial Initiatives In Second Half Of The Year

Press Releases

AEye Reports First Quarter 2025 Results

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for AEye's Current Board and Management and Recommend Rejecting Dissident Group Nominees

AEye Wins Support for Directors and Long-Term Strategy at 2025 Annual Meeting

AEye's Apollo Lidar Sensor Wins Prestigious AIIA Intelligent Perception Industry Leadership Award

AEye Chosen as the Lidar Partner for GM-Sponsored All-Weather Autonomy Research Project at the University of Toronto

Drone-as-a-Service Set to Nearly Triple to $31 Billion by 2030: Four Stocks to Watch

AEye's Apollo Sensor Selected by Major OEM Unlocking Potential $30M Revenue Opportunity

AEye to Report Second Quarter 2025 Financial Results on Thursday, July 31

Apollo Now Fully Integrated into NVIDIA's Autonomous Driving Platform, Paving the Way for Significant Growth

AEye Launches OPTIS™: A Complete Physical AI Solution, Powered by NVIDIA's Jetson Orin, that Delivers the Future of Smart Transportation, Safety, and Security

LIDR

RCAT

UAVS

ZENA

Acorn Energy

PowerFleet

Astrotech

Coda Octopus Group

Electro-Sensors

Focus Universal

Frequency Electronics, Inc. - Common Stock

Frequency Electronics

Identiv

Interlink Electronics, Inc. - Common Stock

Interlink Electronics

LightPath Technologies, Inc. - Class A Common Stock

LightPath Technologies

908 Devices

MultiSensor AI Holdings, Inc. - Common Stock

MultiSensor AI Holdings

Maris Tech

Microvision

NOVONIX Limited - American Depository Shares

NOVONIX

Research Frontiers Incorporated - Common Stock

Research Frontiers

SmartRent

Sono-Tek

ScanTech AI Systems

TROOPS

Unusual Machines

Vishay Precision Group, Inc. Common Stock

Vishay Precision Group

Vuzix

Wrap Technologies

Zepp Health Corporation American depositary shares, each representing sixteen Class A ordinary shares

Comments

AEye

Intérêt court

AEye (NASDAQ:LIDR) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL